

## CURRICULUM VITAE

### **Tony J. DeMartini, M.D., FACC**

Business Address: Prairie Cardiovascular Consultants, LTD  
Baylis Building at Memorial Medical Center  
747 North Rutledge  
Springfield, IL 62702

### Education

Saint Louis University, St. Louis, Missouri, attended 1988-1992  
B.A. Biology, graduated cum laude

Loyola University Stritch School of Medicine, Maywood, Illinois, attended 1992-1996  
M.D.

### Training

Resident in Combined Internal Medicine and Pediatrics  
Loyola University Medical Center, Maywood, Illinois, training 1996-2000

Fellow in Adult Cardiology  
Loyola University Medical Center, Maywood, Illinois, training 2000-2003

Interventional Fellow in Adult Cardiology  
Loyola University Medical Center, Maywood, Illinois, training 2003-2004

### Honors/Positions

House Staff Committee, 1997-2000  
Associate Chief Resident, Department of Medicine, 1999-2000  
Chief Fellow, Department of Cardiology, 2002-2003  
Interventional Chief Fellow, Department of Cardiology, 2003-2004  
Proctor for Chronic Total Occlusion, 2006  
Rotablator Courses, 2006-07

### Licensing

American Board of Internal Medicine	August 2000
American Academy of Pediatrics	October 2000
Adult Cardiology, ABIM	November 2003
Interventional Cardiology	November 2004

Fellow, American College of Cardiology  
State of Illinois  
State of Illinois, Controlled Substances  
Federal DEA

January 2005  
Number available upon request  
Number available upon request  
Number available upon request

Committees: Clinical Competency Committee (CCC)  
Southern Illinois University  
Springfield, IL 62794

Educational Innovation Project (EIP) (Outpatient Quality Improvement Group)  
Southern Illinois University  
Springfield, IL 62794

Facility Privileges:

Prairie Cardiovascular Consultants, Ltd., 7/2004  
619 E. Mason Street  
Springfield, IL 62794

Southern Illinois University School of Medicine, 7/2004  
P.O. Box 19636  
Springfield, IL 62794-9636

St. John's Hospital, 7/2004  
800 E. Carpenter Street  
Springfield, IL 62769

Memorial Medical Center, 7/2004  
701 North 1<sup>st</sup> Street  
Springfield, IL 62781

Prairie Cardiovascular Consultants  
Baylis Building at Memorial Medical Center, 7/2004  
747 N. Rutledge Street, 4<sup>th</sup> Floor  
Springfield, IL 62702

Facility Privileges: (Cont)

Prairie Diagnostic Center 9/2006  
401 East Carpenter

Springfield, IL 62702

Abstracts/Presentations/Posters

**DeMartini TJ**, Muraskas JK. Pulse versus tapered dosing dexamethasone for evolving bronchopulmonary dysplasia. *Pediatric Research*. 45(4);300A; May 1999.

**DeMartini TJ**, Loeb HS. False-Positive Troponin Due to Heterophilic Anti-Murine Antibodies. Chicago Cardiology Group, Chicago, Illinois, March 27, 2003, Presenting Author.

Sundrani R, Jeske WP, Saulters J, Lewis B, Steen L, Sochanski M, Grassman ED, Leya F, Walenga J, **DeMartini TJ**. Platelet and Inflammatory Changes after Angioplasty and Brachytherapy. Chicago Cardiology Group, Chicago, Illinois, March 27, 2003. Presenting Author.

**DeMartini TJ**, Goodfellow RJ, Grassman ED, Lewis B, Steen L, Leya F. Correlation of Change in Pressure over Change in Time (dp/dt) and V-wave timing with Left Atrial Compliance in Patients with Mitral Stenosis. Illinois ACC, Chicago, Illinois, May 14, 2003. Presenting Author

Goodfellow RJ, **DeMartini TJ**, Grassman ED, Lewis B, Steen L, Leya F. Hemodynamic Changes of the Left Atrial V-Wave Following Balloon Mitral Valvuloplasty. Illinois ACC, Chicago, Illinois, May 14, 2003.

Lewis BE, **DeMartini TJ**, Cochran KJ, Grassman ED, Steen LH, O'Brien JW, Wrona L, Leya F. Comparison of Three Direct Thrombin in Patients with Heparin-Induced Thrombocytopenia Undergoing Percutaneous Intervention. International Congress on Coronary Artery Disease, Florence, Italy, October 20, 2003. Presenting Author.

Jeske W, Maszak G, **DeMartini TJ**, Iqbal O, Cho L, Lewis, B, Leya F, Walenga, JM. Sirolimus Coated Stents Induce a Weaker Inflammatory Response Than Bare-Metal Stents. AHA, New Orleans, Louisiana, November, 2004.

Publications

**DeMartini TJ**, Loeb HS. False Positive Troponin I due to Heterophilic Anti-Murine Antibodies. Accepted for publication, *Annals of Internal Medicine*, 2003 December 2; 139 (11): W82

Cochran KJ, **DeMartini TJ**, Lewis BE, Obrien J, Steen LH, Grassman ED, Laya F. Use of Lepirudin during Percutaneous Vascular Interventions in Patients with Heparin-Induced Thrombocytopenia. Accepted for publication, *The Journal of Invasive Cardiology*, 2003 November: 15 (11): 617-21.

### Research

The Medicines Company – Mishkel/Aguirre – The Acuity Trial: A randomized comparison of Angiomax (bivalirudin) vs Lovenox (enoxaparin) in patients undergoing early invasive management for acute coronary syndromes w/out ST-segment elevation. 2003 – Present.

Boston Scientific – Mishkel – TAXUS ATLAS – A multicenter, single-arm study of the Taxus Liberte’<sup>TM</sup> SR stent for the treatment of patients with de novo coronary artery lesions. 2004 – Present.

DUKE – Aguirre – Kinetics of Integrelin Limited by Obesity (KILO), 2003 – Present.

Cleveland Clinic – Low Molecular Weight Heparin (Lovenox) for use in Trans Esophageal echocardiography Guided Cardioversion of Patients with Atrial Fibrillation (ACUTE II) 2003 – Present.

“WATCHMAN”, a pilot study designed to demonstrate the safety of the WATCHMAN device in patients with non-valvular atrial fibrillation (AF) who require treatment for potential thrombus formation, are eligible for warfarin therapy, and have a CHAD stroke risk stratification score of 1 or greater. Atritech, Inc. 09/04.

“PROTECT AF, a pivotal study designed to demonstrate the safety and effectiveness of the WATCHMAN implant in patients with non-valvular atrial fibrillation (AF), persistent or permanent a-fib who require treatment for potential thrombus formation, are eligible for warfarin therapy, and have a CHAD stroke risk stratification score of 1 or greater. Atritech, Inc. 01/05.

“APPROACH”, a Phase III, 18 month, multicenter, randomized, double-blind, active-controlled clinical trial to compare Rosiglitazone versus Glipizide on the progression of atherosclerosis in subjects with Type 2 diabetes and cardiovascular disease. 03/2005. Primary Investigator.

“GE DXV”, a Phase 3, open-level, multicenter study to determine efficacy and safety of VISIPAQUE (iodixanol) injection for use in intravenous contrast-enhanced CT

angiography of coronary arteries. Protocol Number: DXV301. 5/2006 Enrolled 3<sup>rd</sup> patient worldwide. Sub-investigator.

“Zomaxx II”, a randomized, controlled trial to evaluate the safety and efficacy of the Zomaxx drug eluting coronary stent system as compared to the Taxus drug eluting stent express paclitaxel-eluting stent in de novo coronary artery lesion. (The Zomaxx II Trial), Protocol Number: 640-0048. 9/2005. Sub-investigator.